GlassScriptPhysician profile
Donald R Fleming
NPI 1912976507
$10,786.88
in general payments reported to CMS, 2019-2025
32 companies · $2,375 in 2025
The $2,375 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $798 · 2021: $1,329 · 2022: $951 · 2023: $985 · 2024: $3,516 · 2025: $2,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,233 · Food and Beverage: $522 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,232.94 |
| Food and Beverage | $522.01 |
| Education | $121.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $2,232.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,148.21 | 2019-2024 | Tagrisso, Lynparza, Imfinzi |
| Incyte Corporation | $1,100.00 | 2025 | |
| Genzyme Corporation | $849.50 | 2019-2022 | |
| Abbvie INC. | $615.00 | 2019 | |
| Beigene, LTD. | $600.00 | 2023 | Brukinsa |
| Zoll Medical Corporation | $400.00 | 2025 | Defibrillator |
| Immunocore Limited | $400.00 | 2025 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Alnylam Pharmaceuticals INC. | $310.00 | 2022 | |
| Melinta Therapeutics, LLC | $294.00 | 2021 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $151.44 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $110.29 | 2020-2024 | Opdivo, Abilify |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $103.09 | 2020-2024 | Zejula |
| Comsort, INC | $100.00 | 2019 | |
| Celgene Corporation | $92.90 | 2021-2023 | Reblozyl, Pomalyst |
| Pfizer INC. | $92.47 | 2019-2025 | |
| Lilly USA, LLC | $74.59 | 2023 | Retevmo, Jaypirca |
| Seagen INC. | $64.99 | 2020 | |
| Sobi, INC | $46.89 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $41.04 | 2021 | |
| Amgen INC. | $39.21 | 2023 | Kyprolis, Lumakras |
| Aveo Pharmaceuticals, INC. | $37.12 | 2021-2022 | |
| Acrotech Biopharma INC. | $25.90 | 2021 | |
| Kyowa Kirin, INC. | $23.50 | 2022 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Caris Mpi, INC. | $20.59 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $15.52 | 2019 | |
| Sumitomo Pharma America, INC. | $14.77 | 2025 | Orgovyx |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.